- People who take angiotensin converting enzyme inhibitors (ACE-i) or angiotensin II receptor blockers (ARBs) for conditions such as high blood pressure were less likely to be diagnosed with colorectal cancer after having a normal colonoscopy.
- This is the first study to show potential benefits on colorectal cancer development from these commonly prescribed hypertension medications, based on a study of more than 185,000 patients.
Embargoed until 4 a.m. CT/5 a.m. ET Monday, July 6, 2020
DALLAS, July 6, 2020 — Medications commonly prescribed to treat high blood pressure may also reduce patients’ colorectal cancer risk, according to new research published today in Hypertension, an American Heart Association journal.
Angiotensin converting enzyme inhibitor (ACE-i) or angiotensin II receptor blocker (ARB) medications are prescribed for conditions such as heart failure, high blood pressure or heart disease. These medications inhibit or block angiotensin, a chemical that causes arteries to become narrow. Doctors commonly prescribe these medications to people with high blood pressure to relax and open blood vessels, thereby lowering blood pressure.
Based on the findings of this large study, taking these medications may also reduce colorectal cancer risk. Colorectal cancer is the third most common cancer and is the second leading cause of cancer death worldwide.
“The roles of ACE inhibitors and ARBs on cancer development are controversial and, in some cases, study findings are conflicting. Results of previous studies have been limited by several factors including a small number of patients and data only on short-term follow-ups. Our results provide new insights on a potential role of these medications for colorectal cancer prevention,” said study author Wai K. Leung, M.D., clinical professor of medicine at the University of Hong Kong in Hong Kong, China. “This is the first study to show the potential beneficial effects of ACE inhibitors and ARBs on colorectal cancer development, based on a large group of patients who were colorectal cancer-free at the beginning of the study.”
Researchers reviewed health records of 187,897 adult patients in Hong Kong from 2005 to 2013, with a negative baseline colonoscopy for colorectal cancer. The analysis found that:
- those who took hypertension medications such as ACE-i or ARBs had a 22% lower risk of developing colorectal cancer in the subsequent three years;
- the benefits of ACE-i and ARBs were seen in patients 55 or older and those with a history of colon polyps; and
- the benefit associated with the medications was limited to the first three years after the negative baseline colonoscopy.
“While ACE-i and ARBs are taken by patients with high blood pressure, heart failure and kidney diseases, the reduction in colorectal cancer risk may be an additional factor for physicians to consider when choosing anti-hypertensive medications,” Leung said.
This is a retrospective study, looking back at whether patients on these medications developed colorectal cancer. Researchers note that the results should be verified with a prospective randomized controlled study, which would actively follow patients to determine the potential benefits of these medications on colorectal cancer risk.
Co-authors are Ka Shing Cheung, M.B.B.S., M.P.H.; Esther W. Chan, Ph.D.; Wai Kay Seto, M.D.; and Ian C.K. Wong, Ph.D.
The Health and Medical Research Fund of the Hong Kong SAR Government funded this study.
- Available multimedia is on right column of release link - https://newsroom.heart.org/news/common-hypertension-medications-may-reduce-colorectal-cancer-risk?preview=d2e5a1e2b2569d4f74c1e69580290461
- After Monday, July 6, please view the manuscript online.
- Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician
- Know Your Risk Factors for High Blood Pressure
- Follow AHA/ASA news on Twitter @HeartNews
- Follow news from the AHA’s Hypertension journal @HyperAHA
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
William Westmoreland: 214-706-1232, firstname.lastname@example.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)